GlaxoSmithKline (GSK) Misses Q2 EPS by 71c

GlaxoSmithKline (NYSE: GSK) reported Q2 EPS of GBP0.47, GBP0.71 worse than the analyst estimate of GBP1.18. Revenue for the quarter came in at GBP7.99 billion versus the consensus estimate of GBP10.58 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• General Mills beats estimates as cost savings offset volumes
• Scotiabank reaffirms Aya Gold & Silver Inc (AYA:CN) to Sector Outperform on new drilling results